These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 9556193)

  • 1. Clinical uroselectivity: a 3-year follow-up in general practice. BPH Group in General Practice.
    Lukacs B; Grange JC; McCarthy C; Comet D
    Eur Urol; 1998; 33 Suppl 2():28-33. PubMed ID: 9556193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prospective follow-up of 3,228 patients suffering from clinical benign prostatic hyperplasia (BPH) treated for 3 years wi alfuzosin in general practice. BPH Group in General Practice].
    Lukacs B; Grange JC; Comet D; Mc Carthy C
    Prog Urol; 1999 Apr; 9(2):271-80. PubMed ID: 10370951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective study of men with clinical benign prostatic hyperplasia treated with alfuzosin by general practitioners: 1-year results.
    Lukacs B; Leplège A; Thibault P; Jardin A
    Urology; 1996 Nov; 48(5):731-40. PubMed ID: 8911517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. One-year follow-up of 2829 patients with moderate to severe lower urinary tract symptoms treated with alfuzosin in general practice according to IPSS and a health-related quality-of-life questionnaire. BPM Group in General Practice.
    Lukacs B; Grange JC; Comet D
    Urology; 2000 Apr; 55(4):540-6. PubMed ID: 10736498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Three-year prospective study of 3228 clinical BPH patients treated with alfuzosin in General Practice.
    Lukacs B; Grange JC; Comet D; McCarthy C
    Prostate Cancer Prostatic Dis; 1998 Sep; 1(5):276-283. PubMed ID: 12496888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term quality of life in patients with benign prostatic hypertrophy: preliminary results of a cohort survey of 7,093 patients treated with an alpha-1-adrenergic blocker, alfuzosin. QOL BPH Study Group in General Practice.
    Lukacs B; McCarthy C; Grange JC
    Eur Urol; 1993; 24 Suppl 1():34-40. PubMed ID: 7687557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical uroselectivity of alfuzosin is not significantly affected by the age of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
    Sánchez-Chapado M; Guil M; Badiella LI; Fernández-Hernando N; Alfaro V
    BJU Int; 2000 Sep; 86(4):432-8. PubMed ID: 10971267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical uroselectivity of alfuzosin in the treatment of benign prostatic hyperplasia.
    Kirby RS
    Eur Urol; 1998; 33 Suppl 2():19-27. PubMed ID: 9556192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of sustained-release alfuzosin 5 mg in patients with benign prostatic hyperplasia. ALGEBI Study Group.
    Buzelin JM; Roth S; Geffriaud-Ricouard C; Delauche-Cavallier MC
    Eur Urol; 1997; 31(2):190-8. PubMed ID: 9076465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia.
    McKeage K; Plosker GL
    Drugs; 2002; 62(4):633-53. PubMed ID: 11893233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter observational trial on symptomatic treatment of benign prostatic hyperplasia with alfuzosin: clinical evaluation of impact on patient's quality of life. The Italian Alfuzosin Cooperative Group.
    Eur Urol; 1995; 27(2):128-34. PubMed ID: 7538083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group.
    van Kerrebroeck P; Jardin A; Laval KU; van Cangh P
    Eur Urol; 2000 Mar; 37(3):306-13. PubMed ID: 10720857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 24-30 month survey. BPHALF Group.
    Jardin A; Bensadoun H; Delauche-Cavallier MC; Stalla-Bourdillon A; Attali P
    Br J Urol; 1994 Nov; 74(5):579-84. PubMed ID: 7530121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term safety and efficacy of a once-daily formulation of alfuzosin 10 mg in patients with symptomatic benign prostatic hyperplasia: open-label extension study.
    van Kerrebroec P; Jardin A; van Cangh P; Laval KU;
    Eur Urol; 2002 Jan; 41(1):54-60; discussion 60-1. PubMed ID: 11999466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alfuzosin for treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia: a systematic review of efficacy and adverse effects.
    MacDonald R; Wilt TJ
    Urology; 2005 Oct; 66(4):780-8. PubMed ID: 16230138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alfuzosin for treatment of benign prostatic hypertrophy. The BPH-ALF Group.
    Jardin A; Bensadoun H; Delauche-Cavallier MC; Attali P
    Lancet; 1991 Jun; 337(8755):1457-61. PubMed ID: 1710750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, efficacy and impact on Patients' quality of life of a long-term treatment with the alpha(1)-blocker alfuzosin in symptomatic patients with BPH. The Italian Alfuzosin Co-Operative Group.
    Eur Urol; 2000 Jun; 37(6):680-6. PubMed ID: 10828668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 12-18 month assessment. BPHALF Group.
    Jardin A; Bensadoun H; Delauche-Cavallier MC; Attali P
    Br J Urol; 1993 Nov; 72(5 Pt 1):615-20. PubMed ID: 10071548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of sustained-release alfuzosin on lower urinary tract symptoms suggestive of benign prostatic hyperplasia in 3,095 Spanish patients evaluated during general practice.
    Sánchez-Chapado M; Guil M; Alfaro V; Badiella L; Fernández-Hernando N
    Eur Urol; 2000 Apr; 37(4):421-7. PubMed ID: 10765072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice.
    Vallancien G; Emberton M; Alcaraz A; Matzkin H; van Moorselaar RJ; Hartung R; Harving N; Elhilali M;
    BJU Int; 2008 Apr; 101(7):847-52. PubMed ID: 18321317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.